Table 2.
Clinical characteristics of the CHB nonsignificant liver fibrosis group (S0-1) and significant liver fibrosis (S2-4) cases ().
| Clinical characteristics | S0-1 | S2-4 | p |
|---|---|---|---|
| Male/female | 16/9 | 21/12 | 1.0 |
| Age (years old) | 35.4 ± 14 | 42 ± 12 | 0.064 |
| Blood cell counts (109/L) | 5.8 ± 0.9 | 5 ± 0.4 | 0.118 |
| Hemoglobin (g/L) | 149 ± 22 | 142 ± 23 | 0.224 |
| Blood platelet (109/L) | 173 ± 20 | 145 ± 17 | 0.04 |
| ALT (U/L) | 60.1 ± 12.3 | 94 ± 11.2 | 0.107 |
| AST (U/L) | 51.2 ± 7.4 | 78 ± 6.3 | 0.109 |
| γ-GT (U/L) | 45.2 ± 13.9 | 67 ± 15 | 0.123 |
| ALP (U/L) | 73.4 ± 7.7 | 104 ± 14.1 | 0.09 |
| T-Bil (μmol/L) | 22.2 ± 8.9 | 32.2 ± 7.2 | 0.761 |
| D-Bil (μmol/L) | 8.3 ± 5.4 | 15.3 ± 3.9 | 0.807 |
| TP (g/L) | 64.8 ± 13 | 69.6 ± 7.3 | 0.148 |
| ALB (g/L) | 36.8 ± 16.2 | 32 ± 5.9 | 0.291 |
| TC (U/L) | 4.3 ± 0.7 | 4.4 ± 1.3 | 0.889 |
| TG (U/L) | 1.47 ± 0.7 | 1.1 ± 0.3 | 0.065 |
| AFP | 10.8 ± 1.7 | 41.9 ± 8.3 | 0.08 |
| INR | 0.9 ± 0.3 | 1.1 ± 0.02 | 0.233 |
| HBV-DNA (107 U/L) | 9.8 ± 0.9 | 4.8 ± 0.6 | 0.743 |
| HBeAg-positive rate (%) | 60% | 72% | 0.399 |